Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10189849 CDK inhibitors

Patent 10189849 was granted and assigned to G1 Therapeutics on January, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
G1 Therapeutics
G1 Therapeutics
Date Filed
March 12, 2018
Date of Patent
January 29, 2019
Patent Applicant
G1 Therapeutics
G1 Therapeutics
Patent Application Number
15918834
Patent Citations Received
‌
US Patent 10927120 CDK inhibitors
‌
US Patent 11364222 Combination therapy for treatment of cancer
0
‌
US Patent 11357779 G1T38 superior dosage regimes
‌
US Patent 10618905 Pyrimidine-based compounds for the treatment of cancer
‌
US Patent 10660896 Transient protection of normal cells during chemotherapy
‌
US Patent 11643416 Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors
0
Patent Inventor Names
Francis X. Tavares
0
Jay C. Strum
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10189849
Patent Primary Examiner
‌
Jeffrey H Murray

Find more entities like US Patent 10189849 CDK inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.